Management of chemotherapy-induced hepatitis B virus reactivation

Yi Hsiang Huang*, Han Chieh Lin, Shou Dong Lee


研究成果: Review article同行評審

14 引文 斯高帕斯(Scopus)


Hepatitis B virus (HBV) reactivation induced by cytotoxic chemotherapy is an important issue in cancer patients. An elevated HBV viral load usually precedes hepatitis flare, and hepatic decompensation and eventual death is not infrequent once viral reactivation is initiated. Reverse seroconversion from hepatitis B surface antigen (HBsAg)-negative to HBsAg-positive would also occur in hepatitis B core antibody (anti-HBc)-positive patients. The risk of HBV reactivation can be attributed to patient viral status and the regimen of chemotherapeutic agents. Chemotherapeutic regimens that contain steroid and rituximab can increase the risk of viral reactivation in lymphoma patients. Consequently, routine HBV marker screening, including HBsAg and anti-HBc, is mandatory prior to chemotherapy for all cancer patients, and prophylactic antiviral treatment is highly recommended for HBsAg-positive cases. However, for patients who are anti-HBc-positive and HBsAg-negative, so-called resolved hepatitis B patients, regular HBV viral load survey during the course of chemotherapy is necessary to early detect HBV reactivation. Currently, the role of antiviral prophylaxis for resolved hepatitis B patients is still unsettled.

頁(從 - 到)359-362
期刊Journal of the Chinese Medical Association
出版狀態Published - 8月 2012


深入研究「Management of chemotherapy-induced hepatitis B virus reactivation」主題。共同形成了獨特的指紋。